Imagine a high-tech replacement pump for the heart that doesn't just push blood, but acts like a real organ. It adjusts itself automatically to the body's needs and uses materials that the body doesn't reject. It's designed to be a permanent alternative for people who can't get a human heart transplant.
Patients with end-stage biventricular heart failure often lack access to heart transplants due to organ shortages. Existing mechanical assist devices often lack the natural pulsatility and autoregulation of a human heart.
An electro-hydraulically driven total artificial heart (Aeson®) that mimics human heart action through pulsatility, autoregulation, and hemocompatibility.
If you are a manufacturer dealing with the lack of permanent heart failure solutions — this project developed Aeson®, a device that mimics a normal heart's action. It provides a credible therapeutic alternative to transplants for end-stage biventricular heart failure.
If you are a hospital dealing with long transplant waiting lists — this project developed a physiologic heart replacement therapy. With 50 centers already trained for commercial implants, it offers a scalable way to treat advanced heart failure.
If you are a firm dealing with blood clotting issues in mechanical pumps — this project developed a bioprosthetic heart focusing on hemocompatibility. It has achieved a cumulative experience of 44 years in patients.
Carmat is extending its manufacturing site to increase production capacity to 500 hearts per year by the end of 2023. They anticipate manufacturing more than ten hearts a month between September and December 2023.
Based on available project data, the specific unit price or cost of the device is not mentioned.
Based on available project data, specific licensing terms are not provided, but the device is developed by CARMAT as a proprietary product (Aeson®).
The device has been treated in 108 patients with a cumulative experience of 44 years, and the longest support duration exceeded 25 months.
Carmat is currently continuing discussions with the FDA to gain market access for Aeson® in the United States.
The project is led by a single partner, CARMAT, a French SME. This 100% industry-led structure indicates a strong focus on commercialization and direct market entry rather than academic research, as evidenced by their focus on manufacturing ramp-up and FDA discussions.
Contact CARMAT in France regarding the Aeson® PHRT system.
Contact us to explore partnership opportunities with CARMAT for cardiac implant distribution.
